# Jyothis T. George

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jyothis-t-george/

## Facts

| Field | Value |
| --- | --- |
| Citations | 10,874 |
| Field | Diabetes Treatment and Management |
| h-index | 51 |
| i10-index | 105 |
| Last Known Institution | Parkinson's UK |
| OpenAlex ID | https://openalex.org/A5034066967 |
| ORCID iD | 0000-0002-5299-775X |
| Works | 241 |

## Researcher papers

- [Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk](https://scholariq.org/papers/effect-of-linagliptin-vs-placebo-on-major-cardiovascular-events-in-adults-with/)
- [How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial](https://scholariq.org/papers/how-does-empagliflozin-reduce-cardiovascular-mortality-insights-from-a-mediation/)
- [Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes](https://scholariq.org/papers/effect-of-linagliptin-vs-glimepiride-on-major-adverse-cardiovascular-outcomes-in/)
- [The kisspeptin-GnRH pathway in human reproductive health and disease](https://scholariq.org/papers/the-kisspeptin-gnrh-pathway-in-human-reproductive-health-and-disease/)
- [Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease](https://scholariq.org/papers/empagliflozin-and-clinical-outcomes-in-patients-with-type-2-diabetes-mellitus/)
- [Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials](https://scholariq.org/papers/empagliflozin-as-adjunctive-to-insulin-therapy-in-type-1-diabetes-the-ease/)
- [Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial](https://scholariq.org/papers/empagliflozin-reduced-mortality-and-hospitalization-for-heart-failure-across-the/)
- [Evaluation of the Effects of Sodium–Glucose Co-Transporter 2 Inhibition with Empagliflozin on Morbidity and Mortality in Patients with Chronic Heart Failure and a Preserved Ejection Fraction: Rationale for and Design of the EMPEROR-Preserved Trial](https://scholariq.org/papers/evaluation-of-the-effects-of-sodium-glucose-co-transporter-2-inhibition-with/)
- [Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial](https://scholariq.org/papers/effects-of-empagliflozin-on-risk-for-cardiovascular-death-and-heart-failure/)
- [The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study](https://scholariq.org/papers/the-potential-for-improving-cardio-renal-outcomes-by-sodium-glucose-co/)
- [Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories](https://scholariq.org/papers/empagliflozin-and-cardiovascular-and-kidney-outcomes-across-kdigo-risk/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)

## Researcher university

- [Parkinson's UK](https://scholariq.org/institutions/parkinson-s-uk/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.